Celularity

New Jersey-based Celularity is a biotechnology company that develops biomaterials for degenerative diseases and therapeutics for hematological malignancies, solid tumors, and autoimmune and degenerative diseases. The company utilizes a variety of placenta-based platforms for its different therapeutics, including Natural Killer (NK) Cells, Chimeric Antigen Receptor T-cells, and exosomes. The company was formed in July 2021, when Celularity merged with GX Acquisition Corp in a transaction valued at USD 138 million. Through this merger, the combined entity began operations under the “Celularity” name and the company began trading on the Nasdaq under the ticker symbol “CELU.” 

As of May 2024, Celularity had developed four five biomaterial solutions for degenerative diseases, with all having received regulatory approval. These include Interfyl (a connective tissue matrix); Biovance (an amniotic membrane allograft); Centaflex (a human placenta tissue matrix); Biovance 3L (a tri-layered amniotic membrane allograft); and Biovance 3L Ocular (a tri-layered amniotic membrane allograft for ocular applications). The company also had four three degenerative disease biomaterial candidates in the discovery stage for tendon, wound coverings, and bone, spine, and dental indications as of the same date.

Furthermore, as of the same date, Celularity had several candidates in various stages of clinical testing for hematological malignancies: two mesenchymal-like adherent stromal cell (MLASC) based therapeutics for the treatment of Facioscapulohumeral muscular dystrophy (FSHD) and autoimmune and degenerative disease, one hybrid T-Cell and Natural Killer Cell therapeutic for autoimmune disease, one T-Cell therapeutic for solid tumor indications, and one Natural Killer Cell therapeutic for aging-related/Senescence. Its MLASC therapeutic for FSHD was in Phase I/II of clinical testing.

Key customers and partnerships

In May 2021, Celularity entered a multi-year partnership with software provider Palantir Technologies to accelerate and advance cellular therapy development. Through the partnership, Celularity aimed to use Palantir’s Palantir Foundry Platform to create more detailed insights from Celularity’s drug discovery, process development, and manufacturing operations. 

In November 2021, the company entered a collaboration agreement with immuno-oncology company Imugene. Through the agreement, Imugene and Celularity aimed to develop a combination of Imugene’s CD19 oncolytic virus technology and Celularity’s CD19 targeting allogeneic chimeric antigen receptors for the treatment of solid tumors.

In January 2023, Celularity and international import/export company CH Trading Group partnered with Tamer Group to distribute Celularity’s regenerative biomaterial solutions to The Organization of Islamic Cooperation (made up of 57 countries), The Gulf Cooperation Council (made up of six countries), and The African Union (made up of 55 countries).